What Researchers Did
Researchers conducted a randomized controlled trial in Argentina to compare hyperbaric oxygen therapy with standard treatment for patients with severe COVID-19 hypoxaemia.
What They Found
The trial was stopped early after an interim analysis of 40 patients (20 per group). Patients receiving hyperbaric oxygen therapy achieved corrected hypoxaemia significantly faster, with a median of 3 days compared to 9 days in the control group.
What This Means for Canadian Patients
This study suggests hyperbaric oxygen therapy could potentially accelerate recovery from severe hypoxaemia in COVID-19 patients. However, its availability and integration into Canadian healthcare settings for this specific indication would require further evaluation and guidelines.
Canadian Relevance
This study was conducted in Argentina and has no direct Canadian connection.
Study Limitations
A major limitation is the small sample size of 40 patients and the early termination of the trial, which may limit the generalizability of the findings.